NCT02338050View on ClinicalTrials.gov

Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

May 31, 2020

Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
BIOLOGICAL

Moxetumomab Pasudotox

Trial Locations (4)

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

80045

Children's Hospital Colorado, Aurora

90027

Childrens Hospital of Los Angeles, Los Angeles

94143

University of California San Francisco, San Francisco

Sponsors

Collaborators (1)

MedImmune LLC
All Listed Sponsors
collaborator

National Marrow Donor Program

OTHER

collaborator

Pediatric Blood and Marrow Transplant Consortium

OTHER

collaborator

MedImmune LLC

INDUSTRY

collaborator

St. Baldrick's Foundation

OTHER

lead

Center for International Blood and Marrow Transplant Research

NETWORK